KRAS and non-small cell lung carcinoma: PI3K signaling has been shown to be essential for KRAS-driven tumorigenesis in vivo, where mutations in Pik3ca (encoding the p110α subunit of PI3K) that result in defective binding to RAS also prevent Kras-driven NSCLC formation and maintenance (84, 85).